1.Wang Y, Li Z, Zhao X, et al. Stroke care quality in China: substantial improvement, and a huge challenge and opportunity. Int J Stroke. 2017;12:229–235.
2.Liu L, Wang D, Wong KS, Wang Y. Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke. 2011;42:3651–3654.
3.Hsieh CY, Chen CH, Chen YC, Kao Yang YH. National survey of thrombolytic therapy for acute ischemic stroke in Taiwan 2003–2010. J Stroke Cerebrovasc Dis. 2013;22:e620-e627.
4.European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25:457–507.
5.Williams JM, Jude MR, Levi CR. Recombinant tissue plasminogen activator (rt-pa) utilisation by rural clinicians in acute ischaemic stroke: A survey of barriers and enablers. Aust J Rural Health. 2013;21:262–267.
6.Reeves MJ, Arora S, Broderick JP, et al. Acute stroke care in the us: Results from 4 pilot prototypes of the paul co.verdell national acute stroke registry. Stroke. 2005;36:1232–1240.
7.Fang J, Kapral MK, Richards J, et al. The registry of canadian stroke network: An evolving methodology. Acta Neurol Taiwan. 2011;20:77–84.
8.Kapral MK, Silver FL, Richards JA, et al. Rigistry of the canadian stroke network progress report 2001–2005. https://www.ices.on.ca/Publications/Atlases-and-Reports/2005/RCSN-progress-report–2001–2005. Accessed 19 April 2018.
9.Schenkel J, Weimar C, Knoll T, et al. R1—systemic thrombolysis in german stroke units—the experience from the german stroke data bank. J Neurol. 2003;250:320–324.
10.Heuschmann PU, Berger K, Misselwitz B, et al. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: The german stroke registers study group. Stroke. 2003;34:1106–1113.
11.Scherf S, Limburg M, Wimmers R, Middelkoop I, Linqsma H. Increase in national intravenous thrombolysis rates for ischaemic stroke between 2005 and 2012: is bigger better?. BMC Neurol. 2016;16:53.
12.Cocho D, Belvis R, Marti-Fabregas J, et al. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology. 2005;64:719–720.
13.Wang Y, Liao X, Zhao X, W et al. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: Analysis of the results from the chinese national stroke registry (cnsr). Stroke. 2011;42:1658–1664.
14.Group of the China Quality Evaluation of Stroke Care and Treatment. Treatment of acute ischemic stroke in China. Chinese Journal of Neurology. 2009;42:223–228.
15.Wang YL, Wu D, Zhou Y, et al. Thrombolysis in the emergency department in China: Results from an emergency department registry in 7 urban hospitals. Chinese Journal of Stroke. 2009;4:23–28.
16.Faiz KW, Sundseth A, Thommessen B, et al. Reasons for low thrombolysis rate in a norwegian ischemic stroke population. Neurol Sci. 2014;35:1977–1982.
17.Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ecass, atlantis, ninds, and epithet trials. Lancet. 2010;375:1695–1703.
18.Kleindorfer D, Kissela B, Schneider A, et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: A population-based study. Stroke. 2004;35:e27–29.
19.Silvestrelli G, Parnetti L, Paciaroni M, et al. Early admission to stroke unit influences clinical outcome. Eur J Neurol. 2006;13:250–255.
20.Mellon L, Hasan H, Lee S, et al. Knowledge of thrombolytic therapy amongst hospital staff: Preliminary results and treatment implications. Stroke. 2015;46:3551–3553.
21.Brown DL, Barsan WG, Lisabeth LD, et al. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med. 2005;46:56–60.
22.Zhou Y, Yang T, Gong Y, et al. Pre-hospital delay after acute ischemic stroke in central urban China: Prevalence and risk factors. Mol Neurobiol. 2017;54:3007–3016.
23.Yin X, Yang T, Gong Y, et al. Determinants of emergency medical services utilization among acute ischemic stroke patients in hubei province in China. Stroke. 2016;47:891–894.
24.Mishra NK, Lyden P, Grotta JC, et al. Thrombolysis is associated with consistent functional improvement across baseline stroke severity: A comparison of outcomes in patients from the virtual international stroke trials archive (vista). Stroke. 2010;41:2612–2617.
25.Pandian JD, Kalra G, Jaison A, et al. Factors delaying admission to a hospital-based stroke unit in india. J Stroke Cerebrovasc Dis. 2006;15:81–87.
26.Kim YS, Park SS, Bae HJ, et al. Stroke awareness decreases prehospital delay after acute ischemic stroke in korea. BMC Neurol. 2011;11:2.
27.Hong KS, Bang OY, Kim JS, et al. Stroke statistics in korea: Part ii stroke awareness and acute stroke care, a report from the korean stroke society and clinical research center for stroke. J Stroke. 2013;15:67–77.
28.Schwamm LH, Fonarow GC, Reeves MJ, et al. Get with the guidelines-stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation. 2009;119:107–115.
29.Hinchey JA, Shephard T, Tonn ST, et al. Benchmarks and determinants of adherence to stroke performance measures. Stroke. 2008;39:1619–1620.
30.Su QJ, Lin PX, Long FQ, et al. The reasons why acute ischemic stroke patients are treated with thrombolysis in hainan province. Chinese Journal of Heart Brain Vessel diseases. 2015;17:1058–1060.
31.Itrat A, Taqui A, Cerejo R, et al. Telemedicine in prehospital stroke evaluation and thrombolysis: Taking stroke treatment to the doorstep. JAMA Neurol. 2016;73:162–168.
32.Chalouhi N, Dressler JA, Kunkel ES, et al. Intravenous tissue plasminogen activator administration in community hospitals facilitated by telestroke service. Neurosurgery. 2013;73:667–671; discussion 671–662.
33.Amorim E, Shih MM, Koehler SA, et al. Impact of telemedicine implementation in thrombolytic use for acute ischemic stroke: The university of pittsburgh medical center telestroke network experience. J Stroke Cerebrovasc Dis. 2013;22:527–531.